{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:42:15Z","timestamp":1777956135975,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FP086-2019A"],"award-info":[{"award-number":["FP086-2019A"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2019\/SKK08\/UM\/02\/10"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK08\/UM\/02\/10"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpet.2025.103655","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:28:30Z","timestamp":1752571710000},"page":"103655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiproliferative effects of dihydrotanshinone I on autosomal dominant polycystic kidney disease via immunomodulation"],"prefix":"10.1016","volume":"392","author":[{"given":"Rhubaniya","family":"Mahendran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7589-5150","authenticated-orcid":false,"given":"Soo Kun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kien Chai","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kek Heng","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9752-1459","authenticated-orcid":false,"given":"Hwa Chia","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib1","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.jpet.2025.103655_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5414\/CN109247","article-title":"Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study","volume":"89","author":"Nowak","year":"2018","journal-title":"Clin Nephrol"},{"issue":"10174","key":"10.1016\/j.jpet.2025.103655_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103655_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fped.2017.00279","article-title":"The genetic and cellular basis of autosomal dominant polycystic kidney disease-a primer for clinicians","volume":"5","author":"Cordido","year":"2017","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.jpet.2025.103655_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.jpet.2025.103655_bib6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.jpet.2025.103655_bib7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ajhg.2022.06.013","article-title":"Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis","volume":"109","author":"Lemoine","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jpet.2025.103655_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.jpet.2025.103655_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.bcp.2007.08.009","article-title":"Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis","volume":"74","author":"Tsai","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib12","doi-asserted-by":"crossref","first-page":"19387","DOI":"10.3390\/ijms160819387","article-title":"15,16-Dihydrotanshinone I from the functional food Salvia miltiorrhiza exhibits anticancer activity in human HL-60 leukemia cells: in vitro and in vivo studies","volume":"16","author":"Liu","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103655_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15430\/JCP.2018.23.2.63","article-title":"Anti-proliferative effect of 15,16-dihydrotanshinone I through cell cycle arrest and the regulation of AMP-activated protein kinase\/Akt\/mTOR and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells","volume":"23","author":"Hong","year":"2018","journal-title":"J Cancer Prev"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/PAS.0b013e318271eff9","article-title":"Localized cystic disease of the kidney: distinction from cystic neoplasms and hereditary polycystic diseases","volume":"37","author":"Ding","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"mTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11255-018-1951-5","article-title":"The association between autosomal dominant polycystic kidney disease and cancer","volume":"51","author":"Sun","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103655_bib17","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.jpet.2025.103655_bib18","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/hmg\/ddp190","article-title":"Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways","volume":"18","author":"Happ\u00e9","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s004670000495","article-title":"Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice","volume":"16","author":"Nakanishi","year":"2001","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpet.2025.103655_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104254","article-title":"Pharmacological activities of dihydrotanshinone I, a natural product from Salvia miltiorrhiza Bunge","volume":"145","author":"Chen","year":"2019","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.jpet.2025.103655_bib22","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1021\/np2003512","article-title":"Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa","volume":"74","author":"Hong","year":"2011","journal-title":"J Nat Prod"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bcp.2015.03.015","article-title":"Mechanisms of tolvaptan-induced toxicity in HepG2 cells","volume":"95","author":"Wu","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2025.103655_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41420-019-0156-8","article-title":"Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism","volume":"5","author":"Zhao","year":"2019","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.jpet.2025.103655_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.21327","article-title":"Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications","volume":"35","author":"Wang","year":"2015","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/09553002.2022.1998712","article-title":"Responses of genes of DNA repair, alternative oxidase, and pro-\/antioxidant state in Arabidopsis thaliana with altered expression of AOX1a to gamma irradiation","volume":"98","author":"Belykh","year":"2022","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10020-023-00664-z","article-title":"Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion","volume":"29","author":"Wilk","year":"2023","journal-title":"Mol Med"},{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib28","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1681\/ASN.2017080878","article-title":"Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease","volume":"29","author":"Tan","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11248-016-9986-9","article-title":"Phenotypic characterization of a novel HO-1 depletion model in the rat","volume":"26","author":"Atsaves","year":"2017","journal-title":"Transgenic Res"},{"issue":"15","key":"10.1016\/j.jpet.2025.103655_bib30","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.3390\/ijms22158083","article-title":"Effects of dihydrotanshinone I on proliferation and invasiveness of paclitaxel-resistant anaplastic thyroid cancer cells","volume":"22","author":"Allegri","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jpet.2025.103655_bib31","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.31557\/APJCP.2021.22.7.2177","article-title":"Dihydrotanshinone-I modulates epithelial mesenchymal transition (EMT) thereby impairing migration and clonogenicity of triple negative breast cancer cells","volume":"22","author":"Kashyap","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jpet.2025.103655_bib32","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.1038\/s41598-024-58495-9","article-title":"Dihydrotanshinone I exhibits antitumor effects via \u03b2-catenin downregulation in papillary thyroid cancer cell lines","volume":"14","author":"Molteni","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jpet.2025.103655_bib33","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.3390\/molecules27123714","article-title":"Dihydrotanshinone I enhances cell adhesion and inhibits cell migration in osteosarcoma U-2 OS cells through CD44 and chemokine signaling","volume":"27","author":"Fan","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib34","doi-asserted-by":"crossref","first-page":"18149","DOI":"10.3390\/ijms160818149","article-title":"A review of cell adhesion studies for biomedical and biological applications","volume":"16","author":"Khalili","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1083\/jcb.201006173","article-title":"The cell biology of polycystic kidney disease","volume":"191","author":"Chapin","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jpet.2025.103655_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-0888-2_2","article-title":"Cell cycle regulation by checkpoints","volume":"1170","author":"Barnum","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.20892\/j.issn.2095-3941.2017.0033","article-title":"Cell cycle regulation and anticancer drug discovery","volume":"14","author":"Bai","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"24","key":"10.1016\/j.jpet.2025.103655_bib38","doi-asserted-by":"crossref","first-page":"20111","DOI":"10.18632\/oncotarget.3933","article-title":"Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.jpet.2025.103655_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315180","article-title":"Dihydrotanshinone I inhibits the lung metastasis of breast cancer by suppressing neutrophil extracellular traps formation","volume":"23","author":"Zhao","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103655_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","article-title":"Therapeutic advances in ADPKD: the future awaits","volume":"35","author":"Capuano","year":"2022","journal-title":"J Nephrol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103655_bib41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/ndt\/gfx349","article-title":"Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease","volume":"33","author":"Soomro","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.jpet.2025.103655_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/genes11020178","article-title":"Transcriptomics reveal altered metabolic and signaling pathways in podocytes exposed to C16 ceramide-enriched lipoproteins","volume":"11","author":"Hammad","year":"2020","journal-title":"Genes (Basel)"},{"issue":"7","key":"10.1016\/j.jpet.2025.103655_bib43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/gtc.13129","article-title":"Revisiting the gene mutations and protein profile of WT 9-12: an autosomal dominant polycystic kidney disease cell line","volume":"29","author":"Chai","year":"2024","journal-title":"Genes Cells"},{"key":"10.1016\/j.jpet.2025.103655_bib44","article-title":"Role of PKD2 in the endoplasmic reticulum calcium homeostasis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103655_bib45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103655_bib46","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of Nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.jpet.2025.103655_bib47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3390\/cells12121584","article-title":"The interplay between immune and metabolic pathways in kidney disease","volume":"12","author":"Qu","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jpet.2025.103655_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib49","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s42003-021-02730-w","article-title":"Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants","volume":"4","author":"Daneshgar","year":"2021","journal-title":"Commun Biol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103655_bib50","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1681\/ASN.0000000507","article-title":"Targeting metabolic reprogramming in polycystic kidney disease","volume":"35","author":"Boletta","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103655_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.34067\/KID.0001052019","article-title":"Interferon regulatory factor-5 in resident macrophage promotes polycystic kidney disease","volume":"1","author":"Zimmerman","year":"2020","journal-title":"Kidney360"},{"issue":"12","key":"10.1016\/j.jpet.2025.103655_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161318","article-title":"Immune checkpoint activity regulates polycystic kidney disease progression","volume":"8","author":"Kleczko","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jpet.2025.103655_bib53","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","article-title":"Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging","volume":"97","author":"Jomova","year":"2023","journal-title":"Arch Toxicol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103655_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/biomimetics7030087","article-title":"The role of the extracellular matrix (ECM) in wound healing: a review","volume":"7","author":"Diller","year":"2022","journal-title":"Biomimetics (Basel)"},{"issue":"6","key":"10.1016\/j.jpet.2025.103655_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pbi.2004.09.015","article-title":"Cell cycle and differentiation","volume":"7","author":"Jakoby","year":"2004","journal-title":"Curr Opin Plant Biol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103655_bib56","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1183\/09031936.00146510","article-title":"Series \u201cmatrix metalloproteinases in lung health and disease\u201d: biological role of matrix metalloproteinases: a critical balance","volume":"38","author":"L\u00f6ffek","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpet.2025.103655_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109646","article-title":"Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease","volume":"72","author":"Zhang","year":"2020","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jimd.12286","article-title":"International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): diagnosis, follow-up, and management","volume":"44","author":"Altassan","year":"2021","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.jpet.2025.103655_bib60","article-title":"Targeting cancer\u2019s sweet spot: UGP2 as a therapeutic vulnerability","volume":"8","author":"Kim","year":"2021","journal-title":"Mol Cell Oncol"},{"issue":"13","key":"10.1016\/j.jpet.2025.103655_bib61","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1158\/0008-5472.CAN-20-3944","article-title":"Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant CAV1\/SREBP1 signaling","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103655_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13148-021-01081-x","article-title":"Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study","volume":"13","author":"Smyth","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"4","key":"10.1016\/j.jpet.2025.103655_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539868X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539868X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:14:57Z","timestamp":1777943697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652539868X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S002235652539868X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103655","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiproliferative effects of dihydrotanshinone I on autosomal dominant polycystic kidney disease via immunomodulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103655"}}